Past events

In this seminar, professionals from Lhasa Limited and Kang Yusheng will evaluate the application of Lhasa's solutions to meet the ICH M7 guidelines, and will explain how to deal with impurities based on a large amount of toxicological knowledge provided by Derek and Sarah Nexus, using case studies.

At the 2021 Toxicology Forum Virtual Summer Meeting Dr. David Ponting, Lhasa Senior Scientist will be chairing a session on Monday 2nd August titled, N-Nitrosamine Impurities in Pharmaceuticals - Potency, Prediction, and Acceptable Limits.

In this virtual event we investigated the new ANVISA guidance for N-Nitrosamines with presentations from ANVISA, Industry - GSK and Libbs Farmacêutica - and Lhasa representatives.

Join Lhasa Limited Senior Scientist, Andrew Thresher, Principal Business Analyst, Simon Gayton, and Principal Global Alliance Manager, Will Drewe, for an insight and overview of Lhasa's Carcinogenicity database (LCDB).

We were delighted to welcome Andrew Teasdale PhD to present within this webinar; Why you should consider controlling your potentially mutagenic impurities outside the lab.

Andrew is currently the chair of AstraZeneca’s Impurity Advisory Board and has a wealth of knowledge developed over the last 20 years of working within the pharmaceutical industry. He is a leading AZ expert for a number of key impurity areas, including mutagenic impurities (MIs).

The International Workshop on (Quantitative) Structure-Activity Relationships in Environmental and Health Sciences is taking place as a virtual event in June 2021. We are delighted that both Dr. Adrian Fowkes and Dr. David Ponting will be virtually presenting poster summaries of their recent work.